Tirzepatide is a novel once-a-week dual glucose-dependent insulinotropic 
polypeptide and glucagon-like peptide-1 receptor agonist, currently under trial 
to assess glycemic efficacy and safety in people with type 2 diabetes. A 
systematic review and meta-analysis were conducted to investigate the efficacy 
of tirzepatide on glycated hemoglobin (HbA1c, %), fasting serum glucose (mg/dL), 
and body weight (kg) in patients with uncontrolled type 2 diabetes (HbA1c > 
7.0%). Mean changes for efficacy and proportions (safety) with corresponding 95% 
confidence intervals (CIs) were used to provide pooled estimates. A total of 
four randomized controlled trials, comprising 2783 patients of whom 69.4% (n = 
1934) were treated with 5 mg (n = 646), 10 mg (n = 641), or 15 mg (n = 647) of 
tirzepatide, were compared to the placebo (n = 192) or the selective GLP-1 
receptor agonist (n = 523). The pooled analysis showed that tirzepatide 
treatment resulted in a greater lowering of the HbA1c (-1.94%, 95% CI: -2.02 to 
-1.87), fasting serum glucose (-54.72 mg/dL, 95% CI: -62.05 to -47.39), and body 
weight (-8.47, 95% CI: -9.66 to -7.27). We also found that improvement in the 
HbA1c levels was still maintained at weeks 26 and 40 from the long-term trials. 
As for safety, only 3% experienced hypoglycemia, and 4% (95% CI: 2 to 6) 
experienced serious adverse events, while the discontinuation of therapy 
percentage was 7% (95% CI: 5 to 8). Tirzepatide significantly improved glycemic 
control and body weight and had an acceptable safety profile, indicating that it 
is an effective therapeutic option for glucose-lowering in patients with type 2 
diabetes mellitus.